Demographic data | Group | P value | |
---|---|---|---|
Control (n = 27) | Intervention (n = 25) | ||
Age (mean ± SD) | 45.0 ± 8.36 | 41.0 ± 8.61 | 0.099 |
Weight (mean ± SD) | 68.0 ± 9.52 | 70.0 ± 9.71 | 0.45 |
BMI (mean ± SD) | 27.4 ± 4.37 | 27.7 ± 4.03 | 0.78 |
BSA (mean ± SD) | 1.7 ± 0.1 | 1.7 ± 0.13 | 0.35 |
Positive family history n (%) | 8 (29.6) | 6 (24.0) | 0.65 |
Regular Menstruation n (%) | 20 (74.1) | 21 (84.0) | 0.38 |
Married n (%) | 26 (96.0) | 22 (88.0) | 0.34 |
Parity (mean±SD) | 2.8 ± 1.96 | 1.88 ± 1.36 | 0.069 |
Primary tumor size mm (mean±SD) | 31.3 ± 19.54 | 41.2 ± 32.78 | 0.364 |
Initial T-stage n (%) | |||
TI | 7 (25.9) | 4 (16.0) | 0.611 |
T2 | 6 (22.2) | 9 (36.0) | |
T3 | 4 (14.8) | 5 (20.0) | |
T4 | 10 (37.0) | 7 (28.0) | |
Tumor grade n (%) | |||
I | 6 (22.2) | 3 (12.0) | 0.657 |
II | 13 (48.1) | 13 (52.0) | |
III | 8 (29.6) | 9 (36.0) | |
Node involvement n (%) | 21 (77.7) | 22 (88.0) | 0.469 |
Hormonal status | |||
ER+ n (%) | 21 (85.0) | 23 (84.0) | 1.00 |
Extent of positivity (mean±SD) | 74.3 ± 25.1 | 59.9 ± 33.9 | 0.104 |
PR+ n (%) | 19 (70.0) | 14 (56.0) | 0.28 |
Extent of positivity (mean±SD) | 48.7 ± 32.7 | 46.78 ± 32.7 | 0.869 |
HER2+ n (%) | 10 (37.0) | 8 (32.0) | 0.43 |
ki67+a n (%) | 15 (55.5) | 19 (76.0) | 0.122 |
ki67 (mean±SD) | 34.8 ± 27.8 | 37.2 ± 23.7 | 0.742 |
Molecular Subtype | |||
HR+/HER2- | 12 (44.4%) | 9 (36%) | 0.98 |
HR+/HER2+ | 11 (40.1%) | 12 (48%) | |
HR-/HER2+ | 2 (7.4%) | 2 (8%) | |
TNBC | 2 (7.4%) | 2 (8%) | |
TILb n (%) | |||
+ | 13 (48.1) | 10 (40.0) | 0.554 |
- | 14 (51.9) | 15 (60.0) |